By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immune Pharmaceuticals, Inc. 

150 Broadway
Suite 1801
New York  New York  10038  U.S.A.
Phone: 646-937-1941 Fax: n/a




Company News
Immune Pharma Release: Company Will Request An Appeal To Regain Compliance With Nasdaq's Minimum Bid Price Rule 1/10/2017 6:47:10 AM
Immune Pharma Announces Immuno-Oncology R&D Update On December 8, 2016 11/22/2016 10:19:07 AM
Immune Pharma Secures Up To $11 Million In New Financing To Be Deployed With A Focus On Bertilimumab Clinical Development 11/17/2016 10:14:03 AM
Immune Pharma Receives FDA Guidance For Low Dose IL-2 In Combination With Phase III Pivotal Trial Of Its AML Therapy Ceplene 10/27/2016 6:44:41 AM
Immune Pharma Announces Formation Of Management Team For Maxim Pharmaceuticals, Inc. (MAXM), Its Pain And Neurology Subsidiary 10/17/2016 11:02:16 AM
Immune Pharma Signs Agreement To Fund Maxim Pharmaceuticals, Inc. (MAXM), Its Pain And Neurology Subsidiary 9/16/2016 8:41:28 AM
Immune Pharma Receives $2 Million Investment In Common Stock At $0.50 Per Share 9/7/2016 9:31:11 AM
Immune Pharma Provides Business And R&D Update And Announces Second Quarter 2016 Financial Results 8/16/2016 12:14:53 PM
Immune Pharma to Form Pain and Neurology Spin Off Company Around AmiKet 7/19/2016 7:47:02 AM
Immune Pharma Release: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 6/28/2016 6:12:57 AM